FONAR Corporation

NASDAQ:FONR

Medical - Devices

Healthcare
$19.09 +0.00%

+$0.00 today

Market cap
$117.76M
Beta
0.95
P/E (TTM)
17.6
EPS (TTM)
$1.08
52W Low $13.62High $19.16

Volume 0.00M

Average 0.08M

FONR EBITDA Margin

EBITDA as a percentage of revenue.

FONAR CorporationNASDAQ: FONR

EBITDA Margin · Q3 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to 14.8%

EBITDA Margin was 14.8% in Q3 FY2026, down 4.9 pp from a year earlier. On a trailing-twelve-month basis it was 15.1%, down 3.2 pp year over year. Over 3 fiscal years it narrowed by 10.6 pp.

Context

  • EBITDA Margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
14.8%-3.2 pp QoQ
Last fiscal yearJun 2025
17.7%-5.5 pp YoY
LTMMar 2026
15.1%-3.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-4.9 pp——
1 year-5.5 pp——
3 years-10.6 pp——
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
17.7%
Year-over-year change
-5.5pp

EBITDA Margin vs competitors

How FONR compares with its peers on the latest reported figures

  • FONR's LTM Mar 2026 EBITDA Margin of 15.1% is the highest of the 6 companies compared; the peer median is -54.5%.
  • Its year-over-year change of -3.2 pp is the 5th highest of 6, against a peer median of +18.1 pp.
  • Over three fiscal years its change of -10.6 pp compares with a peer median of +45.4 pp.
FONR Competitors Peer median
EBITDA Margin for FONR and competitors
Company Period LTM level YoY 3-year change
FONRFONAR CorporationLTM Mar 202615.1% -3.2 pp-10.6 pp
APYXApyx Medical CorporationLTM Mar 2026-4.4% +24.0 pp+40.8 pp
RCELAVITA Medical, Inc.LTM Mar 2026-52.1% +18.1 pp+20.4 pp
LUNGPulmonx CorporationLTM Mar 2026-54.5% +6.4 pp+50.0 pp
HYPRHyperfine, Inc.LTM Mar 2026-216.2% +118.9 pp+812.8 pp
IFRXInflaRx N.V.LTM Mar 2026-144435.8% -111246.8 pp—
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
VANIVivani Medical, Inc.FY2025— ——
Peer median (excluding FONR) -54.5%+18.1 pp+45.4 pp

Competitors are the stored peer set for FONR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue89.93M97.59M98.65M102.88M104.35M
Cost of Revenue46.46M50.58M52.9M57.74M61.44M
Gross Profit43.47M47.01M45.75M45.14M42.91M
Gross Margin48.3%48.2%46.4%43.9%41.1%
Research & Development1.64M1.49M1.57M1.74M1.58M
Selling, General & Admin0029.39M029.73M
Operating Expenses26.38M25.01M30.96M28.6M31.31M
Depreciation & Amortization4.08M4.54M8.8M4.6M4.7M
EBITDA22M27.65M24.61M23.94M18.5M
EBITDA Margin24.5%28.3%25.0%23.3%17.7%
Operating Income17.1M22.01M14.79M16.54M11.6M
Operating Margin19.0%22.6%15.0%16.1%11.1%
Interest Income00002.17M
Interest Expense248.67K346.55K50.13K77K25.61K
Other Income / Expenses567.72K761.69K969.33K2.73M2.18M
Income Before Tax17.67M22.77M15.76M19.27M13.78M
Pre-Tax Margin19.6%23.3%16.0%18.7%13.2%
Income Tax Expense3.99M5.53M3.63M5.17M3.11M
Net Income10.21M12.44M9.38M10.57M8.33M
Net Margin11.4%12.7%9.5%10.3%8.0%
EPS (Basic)1.471.781.351.561.26
EPS (Diluted)1.451.751.321.531.23
Weighted Avg Shares6.61M6.55M6.65M6.35M6.32M
Weighted Avg Shares (Diluted)6.74M6.68M6.77M6.48M6.55M

FONAR Corporation

NASDAQ:FONR

Intrinsic Alpha fair value

Locked

Current Price

$19.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.